Skip to main content

Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation

Annals of Surgical Oncology volume 17, pages 2283–2289 (2010)Cite this article

Abstract

Purpose

This study was designed to analyze the clinical outcomes of the recurrence of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT) and to evaluate the efficacy of a surgical resection in treating such a recurrence.

Methods

A total of 101 adult LDLT recipients with HCC between 1996 and 2007, including 17 who had recurrent HCC, were reviewed. The endpoints analyzed were survival from time of transplant and survival from time of recurrence. Recipient demographics, laboratory valuables, and tumor characteristics were analyzed. Any medical or surgical treatments that had been administered for any recurrence also were considered.

Results

The mean duration until the initial recurrence after LDLT and the mean duration until death after the initial recurrence were 12.9 months and 12.0 months, respectively. A univariate analysis showed that gender, interferon therapy, early posttransplant tumor recurrence, and eligibility for a surgical resection all had a beneficial impact on survival from tumor recurrence. A surgical resection of tumor relapse was the most important variable in our study, and therefore the patients were divided into two groups: surgical therapy group (n = 9), and nonsurgical therapy group (n = 7). Interestingly, the overall survival rates of the surgical group were significantly better than those of the nonsurgical group and were similar to that of the patients without HCC recurrence.

Conclusions

Surgical therapy might be useful for patients who experience a recurrence of HCC after LDLT to improve their outcome, when such treatment is available.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Taketomi A, Soejima Y, Yoshizumi T, et al. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:124–30.

    Article  PubMed  Google Scholar 

  2. Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001–7.

    Article  PubMed  Google Scholar 

  3. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.

    Article  PubMed  Google Scholar 

  4. Furukawa H, Shimamura T, Suzuki T, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Surg. doi:10.1007/s00534-009-0168-5 [Online September 18, 2009].

  5. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451–9.

    Article  PubMed  Google Scholar 

  6. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982–9.

    Article  CAS  PubMed  Google Scholar 

  7. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.

    Article  PubMed  Google Scholar 

  8. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362–71.

    Article  CAS  PubMed  Google Scholar 

  9. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25:310–2.

    Article  PubMed  Google Scholar 

  10. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248:617–25.

    PubMed  Google Scholar 

  11. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272–9.

    Article  PubMed  Google Scholar 

  12. Soejima Y, Taketomi A, Yoshizumi T, et al. Feasibility of left lobe living donor liver transplantation between adults: an 8-year, single-center experience of 107 cases. Am J Transplant. 2006;6:1004–11.

    Article  CAS  PubMed  Google Scholar 

  13. Taketomi A, Kayashima H, Soejima Y, et al. Donor risk in adult-to-adult living donor liver transplantation: impact of left lobe graft. Transplantation. 2009;87:445–50.

    Article  PubMed  Google Scholar 

  14. O’Grady JG, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988;207:373–9.

    Article  PubMed  Google Scholar 

  15. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2007;10:534–40.

    Article  Google Scholar 

  16. Perez Saborido B, de los Galanes SJ, Meneu Diaz JC, et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. Transpl Proc. 2007;39:2304–7.

    Article  CAS  PubMed  Google Scholar 

  17. Kornberg A, Kupper B, Tannapfel A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. doi:10.1016/j.ejso.2009.10.001 [Online October 24, 2009].

  18. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–31.

    CAS  PubMed  Google Scholar 

  19. Yokoyama I, Carr B, Saitsu H, et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991;68:2095–100.

    Article  CAS  PubMed  Google Scholar 

  20. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497–503.

    Article  PubMed  Google Scholar 

  21. Bai DS, Dai Z, Zhou J, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49:460–70.

    Article  CAS  PubMed  Google Scholar 

  22. Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg. 1995;221:734–41.

    Article  CAS  PubMed  Google Scholar 

  23. Hsieh CB, Chou SJ, Shih ML, et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol. 2008;34:906–10.

    PubMed  Google Scholar 

  24. Bassanello M, Vitale A, Ciarleglio FA, et al. Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. Transpl Proc. 2003;35:2991–4.

    Article  CAS  PubMed  Google Scholar 

  25. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank Prof. Brian Quinn for reviewing this manuscript. This study was supported in part by grant from the Scientific Research Fund of the Ministry of Education of Japan.

Author information

Affiliations

  1. Department of Surgery and Science, Graduate School of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan

    Akinobu Taketomi MD, Takasuke Fukuhara MD, Kazutoyo Morita MD, Hiroto Kayashima MD, Mizuki Ninomiya MD, Yoichi Yamashita MD, Toru Ikegami MD, Hideaki Uchiyama MD, Tomoharu Yoshizumi MD, Yuji Soejima MD, Ken Shirabe MD & Yoshihko Maehara MD

Authors
  1. Akinobu Taketomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takasuke Fukuhara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazutoyo Morita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroto Kayashima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mizuki Ninomiya MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoichi Yamashita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Ikegami MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideaki Uchiyama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoharu Yoshizumi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuji Soejima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ken Shirabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshihko Maehara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akinobu Taketomi MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Taketomi, A., Fukuhara, T., Morita, K. et al. Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation. Ann Surg Oncol 17, 2283–2289 (2010). https://doi.org/10.1245/s10434-010-0999-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-0999-y

Keywords

  • Tace
  • Live Donor Liver Transplantation
  • Tumor Relapse
  • Milan Criterion
  • Nonsurgical Group